Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018

  • ID: 4542989
  • Report
  • 965 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • Enlivex Therapeutics Ltd
  • Invectys SA
  • Miltenyi Biotec GmbH
  • Rhizen Pharmaceuticals SA
  • MORE
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides an overview of the Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Chronic lymphocytic leukemia (CLL) is a type of cancer that starts from white blood cells (called lymphocytes) in the bone marrow. It then invades the blood. Symptoms usually develop slowly. Symptoms of CLL include abnormal bruising (if platelets are low), fever, infections that keep coming back (recur), loss of appetite or becoming full too quickly (early satiety) and weight loss. Treatment options include surgery, radiation therapy, chemotherapy or a combination of methods.

Report Highlights:

This latest pipeline guide Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 6, 51, 54, 1, 2, 58, 12 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 7, 10 and 6 molecules, respectively.

Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Lymphocytic Leukemia (CLL) (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • 4SC AG
  • Bayer AG
  • Enlivex Therapeutics Ltd
  • Invectys SA
  • Miltenyi Biotec GmbH
  • Rhizen Pharmaceuticals SA
  • MORE
Introduction

Chronic Lymphocytic Leukemia (CLL) - Overview

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Development

Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment

Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development

Chronic Lymphocytic Leukemia (CLL) - Drug Profiles

Chronic Lymphocytic Leukemia (CLL) - Dormant Projects

Chronic Lymphocytic Leukemia (CLL) - Discontinued Products

Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ACEA Biosciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ADC Therapeutics SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Altor BioScience Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Amgen Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Aptevo Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by ArQule Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Asana BioSciences LLC, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by AstraZeneca Plc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Baliopharm AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bayer AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by BeiGene Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bellicum Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biogen Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bionomics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Biothera Pharmaceutical Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Co, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by CARsgen Therapeutics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celldex Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellectar Biosciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celltrion Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by CrystalGenomics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cyclacel Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Debiopharm International SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Deciphera Pharmaceuticals LLC, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eli Lilly and Co, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Enlivex Therapeutics Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Eureka Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by GeneaMed Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Genentech Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Grupo Ferrer Internacional SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Heidelberg Pharma AG, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hybrigenics SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Igenica Biotherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immatics Biotechnologies GmbH, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corp, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Inflection Biosciences Ltd, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innovent Biologics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Invectys SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Iovance Biotherapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by JHL Biotech Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kancera AB, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kiromic Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Kite Pharma Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ligand Pharmaceuticals Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Loxo Oncology Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by LSK BioPartners Inc, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies SA, H1 2018

Chronic Lymphocytic Leukemia (CLL) - Pipeline by MEI Pharma Inc, H1 2018

List of Figures

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • 4SC AG
  • AbbVie Inc
  • ACEA Biosciences Inc
  • ADC Therapeutics SA
  • Aeglea BioTherapeutics Inc
  • Altor BioScience Corp
  • Amgen Inc
  • Aptevo Therapeutics Inc
  • ArQule Inc
  • Asana BioSciences LLC
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Baliopharm AG
  • Bayer AG
  • BeiGene Ltd
  • Bellicum Pharmaceuticals Inc
  • Biogen Inc
  • Bionomics Ltd
  • Biothera Pharmaceutical Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • CARsgen Therapeutics Ltd
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Cellectar Biosciences Inc
  • Celltrion Inc
  • Cellular Biomedicine Group Inc
  • CrystalGenomics Inc
  • Cyclacel Pharmaceuticals Inc
  • Debiopharm International SA
  • Deciphera Pharmaceuticals LLC
  • Eli Lilly and Co
  • Enlivex Therapeutics Ltd
  • Eureka Therapeutics Inc
  • F. Hoffmann-La Roche Ltd
  • GeneaMed Ltd
  • Genentech Inc
  • Gilead Sciences Inc
  • Grupo Ferrer Internacional SA
  • Heidelberg Pharma AG
  • Hutchison MediPharma Ltd
  • Hybrigenics SA
  • Igenica Biotherapeutics Inc
  • Immatics Biotechnologies GmbH
  • Immunomedics Inc
  • Incyte Corp
  • Inflection Biosciences Ltd
  • Innate Pharma SA
  • Innovent Biologics Inc
  • Invectys SA
  • Iovance Biotherapeutics Inc
  • JHL Biotech Inc
  • Juno Therapeutics Inc
  • Kancera AB
  • Karyopharm Therapeutics Inc
  • Kiromic Inc
  • Kite Pharma Inc
  • LFB SA
  • Ligand Pharmaceuticals Inc
  • Loxo Oncology Inc
  • LSK BioPartners Inc
  • Lymphocyte Activation Technologies SA
  • MEI Pharma Inc
  • MENTRIK Biotech LLC
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • Miltenyi Biotec GmbH
  • Miragen Therapeutics Inc
  • MorphoSys AG
  • NantKwest Inc
  • Nichi-Iko Pharmaceutical Co Ltd
  • Nordic Nanovector ASA
  • Novartis AG
  • Oncternal Therapeutics Inc
  • Ono Pharmaceutical Co Ltd
  • PEP-Therapy SAS
  • Pfizer Inc
  • PIQUR Therapeutics AG
  • Plexxikon Inc
  • Qurient Co Ltd
  • Respiratorius AB
  • Rhizen Pharmaceuticals SA
  • Sandoz International GmbH
  • Sanofi
  • Selvita SA
  • Supratek Pharma Inc
  • Targazyme Inc
  • TCR2 Therapeutics Inc
  • TG Therapeutics Inc
  • Tolero Pharmaceuticals Inc
  • TRACON Pharmaceuticals Inc
  • Trillium Therapeutics Inc
  • TTY Biopharm Company Ltd
  • United BioPharma Inc
  • Verastem Inc
  • Viralytics Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll